Skip to content

A multicenter, prospective, open, cohort study on the efficacy and safety of integrated traditional Chinese and Western medicine in the treatment of chronic kidney disease stage 3-4

A multicenter, prospective, open, cohort study on the efficacy and safety of integrated traditional Chinese and Western medicine in the treatment of chronic kidney disease stage 3-4

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006493
Enrollment
Unknown
Registered
2022-08-15
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease stage 3-4

Interventions

Integrated traditional Chinese and Western medicine treatment group:On the basis of Western medicine treatment scheme, add traditional Chinese medicine treatment scheme

Sponsors

the First Affiliated Hospital of Anhui University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Age 18 ~ 70 years old, ? meet the diagnostic criteria of CKD stage 3-4; ? Blood pressure < 140/90mmhg, blood potassium < 5.5mmol/l, hemoglobin = 80g/l, infection was controlled, and the condition was stable for more than 2 weeks; ? Those who did not use Chinese patent medicine for CKD within 2 weeks before enrollment, or who had used Chinese patent medicine but had a 2-week washout period; ? Sign informed consent.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating patients ? unable to cooperate, such as psychotic patients ? complicated with active malignant tumors, infectious diseases, liver cirrhosis decompensation, hematopoietic system and other serious primary diseases; ? There is acute urinary tract obstructive disease, which needs surgical treatment; ? Severe arrhythmia, heart failure, NYHA grade III or above, or myocardial infarction or cerebrovascular events within 3 months before enrollment; ? Using corticosteroids, non steroidal anti-inflammatory drugs or immunosuppressants; ? Accord with the clinical or pathological diagnosis of diabetes kidney disease; ? Patients are unwilling to participate and refuse to sign informed consent; ? Patients who are participating in other clinical trials

Design outcomes

Primary

MeasureTime frame
EGFR decrease > 40%;Need renal replacement therapy, or enter CKD stage 5;

Secondary

MeasureTime frame
Quality of life survey;Mineral and bone metabolism indicators;Cardiovascular events;

Countries

China

Contacts

Public ContactWang Yiping

the First Affiliated Hospital of Anhui University of Chinese Medicine

wypwyp54@aliyun.com13075580986

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026